Preventing the cardiotoxic effects of anthracyclins. From basic concepts to clinical data;Prévention de la cardiotoxicité des anthracyclines : approche fondamentale des mécanismes mis en jeu ; relations avec les données cliniques

Annales de Cardiologie et d'Angeiologie

Volumn 55, Issue 2, 2006, Pages 104-112

  Delemasure, S ^a   Vergely, C ^a   Zeller, M ^a,b   Cottin, Y ^a,b   Rochette, L ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

Anthracyclines; Cardiotoxicity; Free radicals

Indexed keywords

ACETYLCYSTEINE; ANTHRACYCLINE; ANTIOXIDANT; CARVEDILOL; CHELATING AGENT; DAUNORUBICIN; DIURETIC AGENT; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; MITOXANTRONE; PIRARUBICIN; PROBUCOL; RAZOXANE; TRIMETAZIDINE; VASODILATOR AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CHELATION; CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG USE; HEART; HEART PROTECTION; HUMAN; MORTALITY; OXIDATIVE STRESS; CHEMICALLY INDUCED DISORDER; HEART DISEASE; METABOLISM; REVIEW;

ANTHRACYCLINES; HEART DISEASES; HUMANS;

EID: 33646238968     PISSN: 00033928     EISSN: 17683181     Source Type: Journal    
DOI: 10.1016/j.ancard.2006.02.005     Document Type: Article

References (39)

1. Wojtacki J., Lewicka-Nowak E., and Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risks factors, pathogenesis, detection and prevention: review of the literature. Med. Sci. Monit. 6 (2000) 411-420
2. Dalloz F., Maingon P., Cottin Y., Briot F., Horiot J.C., and Rochette L. Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defences in the rat. Free Radic. Biol. Med. 26 (1999) 785-800
3. Olson R.D., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4 (1990) 3076-3086
4. Minotti G., Cairo G., and Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. FASEB J. 13 (1999) 199-212
5. Li T., and Singal P.K. Adriamycin induced early changes in myocardial antioxydant enzymes and their modulation by probucol. Circulation 102 (2000) 2105-2110
6. Vasquez-Vivar J., Martasek P., Hogg N., Masters B.S., Pritchard K.A., and Kalyanaraman B. Endothelial nitric oxide synthase dependent superoxide generation from adriamycin. Biochemistry 36 (1997) 11293-11297
7. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., and Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxyde. Proc. Natl. Acad. Sci. USA 87 (1990) 1620-1624
8. Fogli S., Nieri P., and Reschi M.C. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 18 (2004) 664-675
9. Weinstein D.M., Mihm M.J., and Bauer J.A. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J. Pharmacol. Exp. Ther. 294 (2000) 396-401
10. Anversa P., Kajstura J., and Olivetti G. Myocytes death in heart failure. Curr. Opin. Cardiol. 11 3 (1996) 245-251
11. Deply E., Hatem S.N., Andrieu N., De Vaumas C., Henaff M., Rucker-Martin C., et al. Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc. Res. 43 (1999) 398-407
12. Childs A.C., Phaneuf S.L., Dirks A.J., Phillips T., and Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochromes C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res. 62 (2002) 4592-4598
13. Billingham M.E., Masson J.W., Bristow M.R., and Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 62 (1978) 865-972
14. Bristow M.R., Masson J.W., and Daniels J.R. The use of myocardial biopsy to monitor cardiotoxicity. Cancer Treat. Rep. 62 (1978) 1607-1608
15. Wojtacki J., Lewicka-Nowak E., and Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risks factors, pathogenesis, detection and prevention: review of the literature. Med. Sci. Monit. 6 (2000) 411-420
16. Von Hoff D.D., Layard M.W., Basa P., Davis H.L., Von Hoff A.L., and Rozencweig M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91 (1979) 710-717
17. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., and Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324 (1991) 808-815
18. Steinherz L.J., Steinherz P.G., Tan T.C., Heller G., and Murphy M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266 (1991) 1672-1676
19. Remme W.J., and Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22 (2001) 1527-1560
20. Perik P.J., De Vries E.G., Boomsma F., van der Graaf W.T., Sleijfer D.T., van Veldhuisen D.J., et al. Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. Anticancer Res. 25 5 (2005) 3651-3657
21. Cottin Y., Touzery C., Dalloz F., Coudert B., Toubeau M., Riedinger A., et al. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin. Cardiol. 21 9 (1998) 665-670
22. Ryberg M., Nielson D., Skovsgaard T., Hansen J., Jensen B.V., and Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. 11 (1998) 3502-3508
23. Lipshultz S.E., Giantris A.L., Lipsitz S.R., Kimball Dalton V., Asselin B.L., Barr R.D., et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 9101 acute lymphoblastic leukemia protocol. J. Clin. Oncol. 20 6 (2002) 1677-1682
24. Kang Y.J., Chen Y., and Epstein P.N. Surexpression of doxorubicin cardiotoxicity by over-expression of catalase in the heart of transgenic mice. J. Biol. Chem. 271 (1996) 12610-12616
25. Yen H.C., Oberley T.D., Vichitbandhas S., Ho Y.S., and St Clair D.K. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Invest. 98 (1996) 1253-1260
26. Lee V., Randhawa A.K., and Singal P.K. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am. J. Physiol. 261 4 Pt 2 (1991) H989-H995
27. Dorr R. Chemoprotectants for cancer chemotherapy. Semin. Oncol. 18 (1991) 48-58
28. Siveski-Iliskovic N., Hill M., Chow D.A., and Singal P.K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 91 (1995) 10-15
29. Piccinini F. Effets protecteurs de la trimétazidine dur la cardiotoxicité de la doxorubicine. Concours Med. 109 (1987) 3479-3483
30. Speyer J.L., Green M.D., Zeleniuch-Jacquotte A., Wernz J.C., Rey M., and Sanger J. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 10 (1992) 117-127
31. Oliveira P.J., Bjork J.A., Santos M.S., Leino R.L., Froberg M.K., Moreno A.J., et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol. Appl. Pharmacol. 200 (2004) 159-168
32. Salvemini D., Wang Z.Q., Stern M.K., Currie M.G., and Misko T.P. Peroxynitrite decomposition catalysts: therapeutics for peroxinitrite-mediated pathology. Proc. Natl. Acad. Sci. USA 95 (1998) 2659-2663
33. Takimoto E., Champion H.C., Li M., Ren S., Rodriguez E.R., Tavazzi B., et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodelling from chronic pressure load. J. Clin. Invest. 115 (2005) 1221-1231
34. Sacco G., Giampietro R., Salvatorelli E., Menna P., Bertani N., Graiani G., et al. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br. J. Pharmacol. 139 (2003) 641-651
35. Zhou S., Starkov A., Forberg M.K., Leino R.L., and Wallace K.B. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 61 (2001) 771-777 (a)
36. Zhou S., Heller L.J., and Wallace K.B. Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol. Appl. Pharmacol. 175 (2001) 60-67 (b)
37. Oliveira P.J., Bjork J.A., Santos M.S., Leino R.L., Froberg M.K., Moreno A.J., et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol. Appl. Pharmacol. 200 (2004) 159-168
38. Murphy M.P. Investigating mitochondrial radical protection using targeted probes. Biochem. Soc. Trans. 32 (2004) 1011-1014
39. Dhanasekaran A., Kotamraju S., Kalivendi S.V., Matsunaga T., Shang T., Keszler A., et al. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage and apoptosis. J. Biol. Chem. 279 (2004) 37575-37587